Resistance to Antimicrobial Agents in Eradication of Helicobacter Pylori Infection

Annals of Cancer Research and Therapy

Volumn 11, Issue 42371, 2003, Pages 129-142

  Kawai, Takashi ^a   Kawakami, Kohei ^b   Kudo, Taku ^b   Takei, Kazuo ^b   Moriyasu, Fuminovi ^b   Takagi, Yuu ^b   Aoki, Tatsuya ^b   Koyanagi, Yasuhisa ^b   Serizawa, Hiromi ^c   Rinbara, Emiko ^d   Noguchi, Masahisa ^d   Sasatsu, Masanori ^d  

^a Tokyo Medical University ^*  (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^d TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Amoxicillin; clarithromycin; drug resistance; eradication; Helicobacter pylori; metronidazole; proton pump inhibitor; triple therapy

Indexed keywords

12 SULFODEHYDROABIETIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; REBAMIPIDE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DILUTION; DRUG USE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; STOMACH ANTRUM; STOMACH BIOPSY; STOMACH MUCOSA; TREATMENT FAILURE; TREATMENT OUTCOME; UPPER GASTROINTESTINAL TRACT;

EID: 5044230363     PISSN: 13446835     EISSN: None     Source Type: Journal    
DOI: 10.4993/acrt1992.11.129     Document Type: Article

References (32)

1. Adamek, RJ., Suerbaum, S., Pfaffenbach, B. and Opferkuch, W. (1998). Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin: Influence on treatment outcome. Am. J. Gastroenterol. 93: 386-389.
2. Aldana, LP., Kato, M, Nakagawa, S., Kawarasaki, M, Mizushima, T., Oda, H., Kodaira, J., Shimizu, Y, Komatsu, Y, Zheng, R., Takeda, H., Sugiyama, T. and Asaka, M. (2002). The Relationship between consumption of antimicrobial agents and prevalence of primary Helicobacter pylori resistance. Helicobacter 7: 306-9
3. Asaka, M., Satoh, K, Sugano, K, Sugiyama, T., Takahashi, S., Fukuda, Y, Ota, H, Murakami, K, Kimura, K. and Shimoyama, T. (2001). Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 6: 177-186
4. Boyanova, L, Mentis, A., Gubina, M., Rozynek, E., Gosciniak, G, Kalenic, S. V. Goral, V, Kupcinskas, L., Kantarceken, B., Aydin, A., Archimandritis, A., Dzierzanowska, D., Vcev, A., Ivabova, K., Marina, M., Mitov, I., Petrov, P., Ozden,A. and popova, M. (2002). The status of antimicrobial resistance of Helicobacter pylori in easten Europe. Clin. Microbiol. Infect. 8: 388-396
5. Debets-Ossenkopp, Y.J., Sparrius, M., Küster, J.G.J.J. Kolkman, J.J. and. Vandenbroucke-Grauls, C.M.J.K. (1996). Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS. Microbiol. Lett 142: 37-42
6. Dore, MP. Graham, D.Y. and Sepulveda, R. (1999). Different penicillin-binding protein profiles in amoxicillin-resistant Helicobacter pylori. Helicobacter 4: 154-161
7. Fontana, C, Favaro, M., Pietroiusti, A., Pistoia, E.S., Galante, A. and Favalli, C. (2003). Detection of clarithromycin-resistant Helicobacter pylori in stool samples. J. Clin. Microbiol. 41: 3636-3640
8. Furuta, T., Naohito, S., Takashima, M., Shirai, N., Xiao, F., Hanai, H., Sugimura, H., Ohashi, K., Ishizaki, Tand Kaneko, E. (2001). Effect of genotypic difference in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Then 69: 158-168
9. Glupcznski, Y, Brautet, N., Cantagrel, A., Andersen, LP., Alarcon, T., Lopez-Brea, M. and Megraud, F. (2002). Comparison of the E test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori. Eur. J. Microbiol. Infect. Dis. 21: 549-552
10. Goodwin, A., Kersulyte, D., Sisson, S., Zanten, S.J.O.V., Berg, D.E. and Hoffman, P.S. (1998). Metronidazole resistance in Helicobacter pylori is duo to null mutation in a gene (rdxA) that encodes anoxgen-insensitive NADPH nitoreductase. Molecular Microbiology 28: 383-393
11. Hokari, K., Sugiyama, T., Kato, M., Saito, M., Miyagishima, T., Kudo, M., Nishikawa, K., Ishizuka, J., Komatsu, Y, Mizushima, T., Kagaya, H., Hige, S., Takeda, H. and Asaka, M. (2001). Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment. Pharmacol. Ther 15: 1479-1484
12. Inaba, T., Mizuno, M., Kawai, K., Yokota, K., Oguma, K., Miyoshi, M, Take, S., Okada, H. and Tsuji, T. (2002). Randomized open trial comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J. Gastroenterol Hepatol 17: 748-753
13. Japanese Society of Chemotherapy. (1981). Method for the determination of minimum inhibitory concentration (MIC) of aerobic bacteria by agar dilution method. Chemotherapy (Tokyo) 29: 76-79.
14. Jeong, J. Y., Mukhopadhyay, A.K. Akada, J.K. Dailodiene, D., Hoffman, PS. and Berg, D. (2001) Roles of FrxA and RdxA nitroreductases of Helicobacter pylori in susceptibility and resistance to metronidazole. J Bacteriol 183: 5155-5162
15. Kamada, T, Haruma, K., Komoto, K., Mihara, M., Chen, X., Yoshihara, M., Sumi, K., Kajiyama, G, Tahara, K and Kawamura, Y. (1999). Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin and clarithromycin. Helicobacter 4: 204-210
16. Kamada, T, Haruma, K., Miyoshi, E., Kitadai, M., Yoshihara, M., Sumi, K., Kajiyama, G, Tahara, K., Murai, T., Kawamura, Y. and Hattori, N. (2000). Cetraxate, a mucosal protective agent, combined with omeprazole, amoxicillin and clarithromycin increases the eradication rate of Helicobacter pylori in smokers. Aliment Pharmacol Ther 14: 1089-1094
17. Kihira, K., Satoh Sajfuku, K, Kawakami, S., Fukazawa, K., Isono, Y, Kimura, K. and Sugano, K. (2000). Rabeprazole, amoxicillin and low- or high-dose clarithromycin for the cure of Helicobacter pylori. Aliment. Pharmacol. Ther. 14: 1083-1087
18. Maeda, S., Yoshida, H., Matsunaga, H., Ogura, K., Kawamata, O., Shiratori, Y. and Omata, M. (2000). Detection of clarithromycin-resistant Helicobacter pylori strains with preferential homo-duplex formation assay. J. Clin. Microbiol 38: 210-214
19. Mendonca, S. Ecclissato, C. Sartori, M.S. Godoy, A.P.O., Guerzoni, RA., Degger, M. and Pedrazzori, J. (2000). Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetoracycline, and Frazolidon in Brazil. Helicobacter 5: 79-83
20. Miwa, H., Ohkura, R, Murai, T, Sato, K., Nagahara, A., Hirai, S., Watanabe S. and Sato.N. (1999). Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection: Comparison with omeprazole and lansoprazole. Aliment. Pharmacol. Ther. 13: 741-746
21. Miwa, H., Misawa, H., Yamada, T, Nagahara, A., Ohtaka, K. and Sato, N. (2001). Clarithromycin resistance, but not CYP2C19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for the cure of H. pylori infection. Dig Dis Sci 46: 2445-2450
22. Miwa, H., Yamada, T, Sato, K., Ohta, K., Ohkura, R., Murai, T, Nagahara, A., Takei, Y, Ogihara, T. and Sato, N. (2000). Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection. Comparison of 20 and 40mg rabeprazole with 60mg lansoprazole. Dig. Dis. Sci. 45: 77-82
23. Murakami, K., Fujioka, T., Okimoto, T., Sato. R., Kodama, M. and Nasu, M. (2002). Drug combination the amoxicillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int. J. Antimicrob. Agent. 19: 67-70
24. Murakami, K., Sato, R., Okimoto, T, Nasu, M., Fujioka, T., Kodama, M. and Kagawa, J. (2001). Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-lone Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment. Pharmacol. Ther. 17: 119-123
25. Murakami, K., Sato, K., Okimoto, T., Nasu, M., Fujioka, T., Kodama, M., Kagawa, J., Sato, S. Abe and Arita, T. (2002). Eradication rates of clarithromycin-resistant Helicobacter pylori using rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment. Pharmacol. Ther. 16: 1933-1938
26. Nagahara, A., Miwa, H., Ohkura, R, Yamada, T., Sato, K., Hojo, M. and Sato, N. (2001). Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J. Gastroenterol. Hepatol 2001: 16: 613-618
27. Okamoto, T., Yoshiyama, H., Nakazawa, T., Park, D., Chang, M.W., Yanai, H., Okita, K. and Shirai, M. (2002). A change in PBP 1 is involved in amoxicillin resistance of clinicl isolates of Helicobacter pylori. J. Antimicrob. Chemother. 50: 849-856
28. Perri, R, Villani, M.R., Festa Quitadamo, V.M. and Andriulli, A. (2001). Predictors f failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 15: 1023-1029
29. Poon, S.K., Chang, CS., SU, J. C. H., Lai, C.H., Yang, C.C., Chen, G.H. and Wang, W.C. (2002). Primary resistance to antibiotics and its clinical impact the efficacy of Helicobacter pylori lansoprazole-based triple therapy. Aliment Pharmacol Ther 16: 291-296
30. Russman, H., Schmidt, A.F., adler, K., Aust, D., Fischer, A. and Koletzko, S. (2003). Detection of Helicobacter pylori in paraffin-embedded and in shock-frozen gastric biopsy samples by fluorescent in situ hybridization. J. Clin. Microbiol. 41: 813-815
31. Tankovic, J., Lamarque, D., Lascols, C., Soussy, C.J. and Delchier, J.C. (2001). Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Aliment. Pharmacol. Ther. 15: 707-713
32. Versalvoic, J., Shortrige, D., KriberK, K., Griffy, M.V. Beyer, J., Flamm, R.K., Tanaka, S.K., Graham, D.Y. and Go, MF. (1996). Mutation in 235 rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob. Agent. Chemother. 40: 477-480